The skin serves as the primary interface between our body and the external environment
and acts as a barrier against entry of physical agents, chemicals, and microbes …

The excellent clinical efficacy of anti-interleukin 17A (IL-17A) biologics on psoriasis indicates
a crucial pathogenic role of IL-17A in this autoinflammatory skin disease. IL-17A accelerates …

Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence
of approximately 2% in the general population worldwide. Psoriasis can be triggered by …

Background: Psoriasis is a common, chronic inflammatory skin disorder, which can
significantly impact quality of life. Despite major breakthroughs in our understanding of the …

Psoriasis is a chronic inflammatory skin disease, the immunologic model of which has been
profoundly revised following recent advances in the understanding of its pathophysiology. In …

Psoriasis is a common inflammatory skin disease with an incompletely understood etiology.
The disease is characterized by red, scaly and well-demarcated skin lesions formed by the …

Summary Interleukin-23 (IL-23) and CD4+ T helper 17 (Th17) cells are thought to be critical
in psoriasis pathogenesis. Here, we report that IL-23 predominantly stimulated dermal γδ T …

Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can
induce and exacerbate psoriasis, a chronic inflammatory skin disorder. Recently, a crucial …

Psoriasis is a chronic, immune‐mediated disease affecting more than 100 million people
worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to …

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …